Garlic extract prevents CCl4-induced liver fibrosis in rats: The role of tissue transglutaminase

Digestive and Liver Disease

Volumn 42, Issue 8, 2010, Pages 571-577

  D'Argenio, Giuseppe ^a   Amoruso, Daniela Caterina ^a   Mazzone, Giovanna ^a   Vitaglione, Paola ^a   Romano, Antonietta ^a   Ribecco, Maria Teresa ^a   D'Armiento, Maria Rosaria ^a   Mezza, Ernesto ^a   Morisco, Filomena ^a   Fogliano, Vincenzo ^a   Caporaso, Nicola ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cystamine; Garlic extract; Liver fibrosis; Tissue transglutaminase

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; CARBON TETRACHLORIDE; COLLAGEN; COLLAGEN FIBER; CYSTAMINE; GARLIC EXTRACT; INTERLEUKIN 1BETA; MESSENGER RNA; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; ACTIN; ENZYME INHIBITOR; PLANT EXTRACT; SMOOTH MUSCLE ACTIN, RAT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HISTOLOGY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; LIVER FIBROSIS; LIVER FUNCTION; LIVER HOMOGENATE; LIVER INJURY; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOENZYMATIC ASSAY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; ENZYMOLOGY; GARLIC; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER CIRRHOSIS; LIVER FUNCTION TEST; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TOXICITY;

ACTINS; ANIMALS; CARBON TETRACHLORIDE; COLLAGEN; CYSTAMINE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENZYME INHIBITORS; GARLIC; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-1BETA; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; PLANT EXTRACTS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSGLUTAMINASES;

EID: 77954387029     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.11.002     Document Type: Article

References (31)

1. Török N.J. Recent advances in the pathogenesis and diagnosis of liver fibrosis. J Gastroenterol 2008, 43:315-321.
2. Wanless I.R., Nakashima E., Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000, 124:1599-1607.
3. Benyon R.C., Iredale J.P. Is liver fibrosis reversible?. Gut 2000, 46:443-446.
4. Iredale J.P., Benyon R.C., Pickering J., et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998, 102:538-549.
5. Iredale J.P. Hepatic stellate cell behaviour during resolution of liver injury. Semin Liver Dis 2001, 21:427-436.
6. Elli L., Bergamini C.M., Bardella M.T., et al. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis 2009, 41:541-550.
7. Greenberg C.S., Birckbichler P.J., Rice R.H. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. Fed Am Soc Exp Biol J 1992, 5:3071-3077.
8. Kojima S., Nara K., Rifkin D.B. Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol 1993, 121:439-448.
9. Lorand L. Neurodegenerative diseases and transglutaminase. Proc Natl Acad Sci U S A 1997, 93:14310-14313.
10. Ikura K., Takahata K., Sasaki Y. Cross-linking of a synthetic partial length (1-28) peptide of the Alzheimer β/A4 amyloid protein by transglutaminase. FEBS Lett 1993, 326:109-111.
11. Lesort M., Tucholski J., Miller M.L., et al. Tissue transglutaminase: a possible role in neurodegenerative diseases. Prog Neurobiol 2000, 61:439-463.
12. Dedeoglu A., Kubilus J.K., Jeitner T.M., et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002, 22:8942-8950.
13. Qiu J.-F., Zhang Z.-Q., Chen W., et al. Cystamine ameliorates liver fibrosis induced by carbon tetrachloride via inhibition of tissue transglutaminase. World J Gastroenterol 2007, 28:4328-4332.
14. Jeitner T.M., Delikatny E.J., Ahlqvist J., et al. Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem Pharmacol 2005, 69:961-970.
15. Dubinsky R., Gray C. CYTE-I-HD Phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov Disord 2006, 21:530-533.
16. Tapiero H., Townsend D.M., Tew K.D. Organosulfur compounds from alliaceae in the prevention of human pathologies. Biomed Pharmacother 2004, 58:183-193.
17. Borek C. Antioxidant health effects of aged garlic extract. J Nutr 2001, 131:1010S-1015S.
18. Singleton V.L., Rossi J.A. Colourimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents. Am J Enol Viticult 1965, 16:144-158.
19. Issa R., Zhou X., Trim N., et al. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J 2003, 17:47-49.
20. Lorand L., Campbell-Wilkes L.K., Cooperstein L. A filter paper assay for transamidating enzyme using radioactive amine substrate. Ann Biochem 1972, 50:623-631.
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
22. Grenard P., Bresson-Hadni S., Alaoui S.E., et al. Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis. J Hepatol 2001, 35:367-375.
23. Karpuj M.V., BecherMW, Springer J.E., et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002, 8:143-149.
24. Lesort M., Lee M., Tucholski J., et al. Cystamine inhibits caspase activity. Implication for the treatment of polyglutamine disorders. J Biol Chem 2003, 278:3825-3830.
25. Chang M.L., Klaidman L.K., Adams J.D. The effects of oxidative stress on in vivo brain GSH turnover in young and mature mice. Mol Chem Neuropathol 1997, 30:187-197.
26. Gedik N., Kabasakal L., Şehirli Ö., et al. Long-term administration of aqueous garlic extract (AGE) alleviates liver fibrosis and oxidative damage induced by biliary obstruction in rats. Life Sci 2005, 76:2593-2606.
27. Amagase H., Petesch B., Matsuura H., et al. Intake of garlic and its bioactive components. J Nutr 2001, 131:955S-962S.
28. Powolny A., Singh S.V. Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer Lett 2008, 269:305-314.
29. Kritchevsky D. The effect of dietary garlic on the development of cardiovascular disease. Trends Food Sci Technol 1991, 2:141-144.
30. Ackerman R., Mulrow C.D., Ramirez G., et al. Garlic shows promise for improving some cardiovascular risk factors. Arch Int Med 2001, 161:813-824.
31. Egen-Schwind C., Eckard R., Kemper F.H. Metabolism of garlic constituents in the isolated perfused rat liver. Planta Med 1992, 58:301-305.